High Cryptococcal Antigenuria Prevalence in a Population of PLHIV with Neurological Symptoms Hospitalized in the Infectious Diseases Wards of the Centre Hospitalier Universitaire De Libreville, Gabon

Overview

Journal Trop Med Infect Dis

Specialty Infectious Diseases

Date 2024 Dec 27

PMID 39728839

Authors

Roger Hadry Sibi Matotou

Denise Patricia Mawili-Mboumba

Charlene Manomba

Bridy Chesly Moutombi Ditombi

Coella Joyce Mihindou

Dimitri Ardin Moussavou Mabicka

Arsene Mounomby

Solange Nzenze Afene

Marielle Karine Bouyou Akotet

Affiliations

Soon will be listed here.

Abstract

Cryptococcal meningitis is a major cause of death in HIV/AIDS patients due to the existence of in the central nervous system. Our objective was to evaluate the prevalence of Cryptococcus antigenuria in a population of HIV-infected patients in Libreville, Gabon. : This study was conducted from April to October 2021 at the Infectious Diseases ward of the Centre Hospitalier Universitaire de Libreville. Hospitalized patients with HIV were included. The detection of cryptococcal antigen (CrAg) in urine was performed using the Pastorex Crypto Plus Kit. : Out of the 255 PLHIV, 142 benefited from the CrAg detection. The prevalence of urine CrAg was 24.6% (n = 35). The majority of CrAg+ patients (82.8%; n = 29) were under 55 years old. Almost three-quarters of them (n = 25; 71.4%) had CD4 counts < 200, and 80.0% (n = 28) were at WHO clinical stages III and IV. All patients with neck stiffness at admission had a CrAg positive test. : This study showed a non-negligible prevalence of Cryptococcal urinary antigen in HIV-infected patients with neurological symptoms. These data underline the importance of CrAg screening in routine care for better management of PLHIV.

References

Drain P, Galagan S, Govere S, Krows M, Thulare H, Wallis C . Laboratory Reflex and Clinic-Based Point-of-Care Cryptococcal Antigen Screening for Preventing Meningitis and Mortality Among People Living With HIV. J Acquir Immune Defic Syndr. 2021; 87(5):1205-1213. PMC: 8263484. DOI: 10.1097/QAI.0000000000002717. View

Govender N, Meintjes G, Mangena P, Nel J, Potgieter S, Reddy D . Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update. South Afr J HIV Med. 2020; 20(1):1030. PMC: 7081625. DOI: 10.4102/sajhivmed.v20i1.1030. View

Temfack E, Kouanfack C, Mossiang L, Loyse A, Fonkoua M, Molloy S . Cryptococcal Antigen Screening in Asymptomatic HIV-Infected Antiretroviral Naïve Patients in Cameroon and Evaluation of the New Semi-Quantitative Biosynex CryptoPS Test. Front Microbiol. 2018; 9:409. PMC: 5859387. DOI: 10.3389/fmicb.2018.00409. View

Aguilar G, Lopez G, Sued O, Medina N, Caceres D, Pereira J . Implementation of a rapid diagnostic assay package for cryptococcosis, histoplasmosis and tuberculosis in people living with HIV in Paraguay. BMC Infect Dis. 2024; 24(1):406. PMC: 11020460. DOI: 10.1186/s12879-024-09257-5. View

Lee Y, Wang J, Sun H, Chen Y . Comparisons of clinical features and mortality of cryptococcal meningitis between patients with and without human immunodeficiency virus infection. J Microbiol Immunol Infect. 2011; 44(5):338-45. DOI: 10.1016/j.jmii.2010.08.011. View

Drain P, Hong T, Krows M, Govere S, Thulare H, Wallis C . Validation of clinic-based cryptococcal antigen lateral flow assay screening in HIV-infected adults in South Africa. Sci Rep. 2019; 9(1):2687. PMC: 6389876. DOI: 10.1038/s41598-018-37478-7. View

Dat V, Lyss S, Dung N, Hung L, Pals S, Anh H . Prevalence of Advanced HIV Disease, Cryptococcal Antigenemia, and Suboptimal Clinical Outcomes Among Those Enrolled in Care in Vietnam. J Acquir Immune Defic Syndr. 2021; 88(5):487-496. PMC: 8575167. DOI: 10.1097/QAI.0000000000002786. View

Meyer A, Kendi C, Penner J, Odhiambo N, Otieno B, Omondi E . The impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in Kenya. Trop Med Int Health. 2013; 18(4):495-503. PMC: 3809891. DOI: 10.1111/tmi.12067. View

Derbie A, Ayalew W, Mekonnen D, Alemu M, Mulugeta Y . Magnitude of Cryptococcal Antigenemia among HIV Infected Patients at a Referral Hospital, Northwest Ethiopia. Ethiop J Health Sci. 2019; 28(4):369-374. PMC: 6308728. DOI: 10.4314/ejhs.v28i4.2. View

10.

Wake R, Ismail N, Omar S, Ismail F, Tiemessen C, Harrison T . Prior Pulmonary Tuberculosis Is a Risk Factor for Asymptomatic Cryptococcal Antigenemia in a Cohort of Adults With Advanced Human Immunodeficiency Virus Disease. Open Forum Infect Dis. 2022; 9(7):ofac202. PMC: 9251663. DOI: 10.1093/ofid/ofac202. View

11.

Scarborough M, Gordon S, Whitty C, French N, Njalale Y, Chitani A . Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J Med. 2007; 357(24):2441-50. PMC: 5068549. DOI: 10.1056/NEJMoa065711. View

12.

Oliveira F, Nakagawa J, de Oliveira J, Lucas Junior R, Marcusso R, Vidal J . High prevalence of central nervous system cryptococcosis using a fingerprick whole-blood lateral flow assay in individuals with neurological symptoms and advanced HIV disease in a Brazilian emergency department. Med Mycol. 2023; 61(9). DOI: 10.1093/mmy/myad093. View

13.

Alemu A, Kempker R, Tenna A, Smitson C, Berhe N, Fekade D . High prevalence of Cryptococcal antigenemia among HIV-infected patients receiving antiretroviral therapy in Ethiopia. PLoS One. 2013; 8(3):e58377. PMC: 3587601. DOI: 10.1371/journal.pone.0058377. View

14.

Drain P, Kleene J, Coleman S, Losina E, Katz J, Giddy J . Prevalence of cryptococcal antigenuria at initial HIV diagnosis in KwaZulu-Natal. HIV Med. 2015; 16(10):640-4. PMC: 4618243. DOI: 10.1111/hiv.12263. View

15.

Letang E, Muller M, Ntamatungiro A, Kimera N, Faini D, Furrer H . Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality. Open Forum Infect Dis. 2015; 2(2):ofv046. PMC: 4511744. DOI: 10.1093/ofid/ofv046. View

16.

Jarvis J, Lawn S, Vogt M, Bangani N, Wood R, Harrison T . Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis. 2009; 48(7):856-62. PMC: 2875173. DOI: 10.1086/597262. View

17.

Wake R, Govender N, Omar T, Nel C, Haeri Mazanderani A, Karat A . Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program. Clin Infect Dis. 2019; 70(8):1683-1690. PMC: 7346756. DOI: 10.1093/cid/ciz485. View

18.

Skipper C, Abassi M, Boulware D . Diagnosis and Management of Central Nervous System Cryptococcal Infections in HIV-Infected Adults. J Fungi (Basel). 2019; 5(3). PMC: 6787675. DOI: 10.3390/jof5030065. View

19.

Burton D . Advancing an HIV vaccine; advancing vaccinology. Nat Rev Immunol. 2018; 19(2):77-78. PMC: 6425752. DOI: 10.1038/s41577-018-0103-6. View

20.

Vianna C, Mosegui G . Cost-Effectiveness Analysis of the Implementation of Cryptococcal Antigen Lateral Flow Assay for the Diagnosis of Cryptococcal Meningitis in Symptomatic People Living With Human Immunodeficiency Virus in Brazil. Value Health Reg Issues. 2021; 29:53-59. DOI: 10.1016/j.vhri.2021.09.006. View